Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.84 +1.63%

+$0.10 today

Market cap
$560.13M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.78M

Average 4.86M

WVE EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Wave Life Sciences Ltd.NASDAQ: WVE

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$23.78M, compared with -$44.71M a year earlier. Trailing-twelve-month EBITDA was -$174.59M.

Context

  • EBITDA amounted to 457.6% of revenue in FY2025, up 376.0 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 15 analysts of -$165.57M (+15.3%) for the fiscal year ending Dec 2026, a step up from the -121.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$23.78M+53.3% QoQ
Last fiscal yearDec 2025
-$195.53M-121.3% YoY
LTMMar 2026
-$174.59M-68.4% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.8%-21.9%-68.7 pp
1 year-121.3%+15.3%+136.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(195.53M) USD
Year-over-year change
-121.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How WVE compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -68.4% is the 7th highest of 10, against a peer median of -44.4%.
  • EBITDA amounts to 243.2% of revenue for WVE, versus a peer median of 148.9%.
WVE Competitors
EBITDA for WVE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.15B USD+773.6%—24.0%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$124.95M USD+217.3%—5.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026-€42.88M EUR-67.7%—319.0%
BNTCBenitec Biopharma Inc.LTM Mar 2026-$53.46M USD-44.4%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-$67.53M USD-3.7%—148.9%
SLNSilence Therapeutics plcLTM Mar 2026-$78.13M USD——8478.5%
STOKStoke Therapeutics, Inc.LTM Mar 2026-$164.11M USD-405.9%—511.5%
WVEWave Life Sciences Ltd.LTM Mar 2026-$174.59M USD-68.4%—243.2%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$384.61M USD+25.4%—581.9%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-$473.54M USD-208.3%—49.3%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-$603.58M USD-466.2%—133.9%
Peer median (excluding WVE) —-44.4%—148.9%

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.